Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia.
Location: Netherlands, Gelderland, Nijmegen
Investors 2
| Date | Name | Website |
| - | BioGenerat... | biogenerat... |
| - | Forbion | forbion.co... |
Mentions in press and media 3
| Date | Title | Description |
| 17.12.2018 | Novo Nordisk grabs a $486M buyout option on an anti-apoC3 antibody for its cardio R&D group | A couple of months after restructuring its R&D operations, Novo Nordisk has whipped up a $486 option deal to buy out Staten Biotechnology — if their lead drug comes through in clinical trials. The main attraction at t... |
| 17.12.2018 | Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline | Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline. Staten has quietly e... |
| 17.12.2018 | Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline | Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline. Sponsored by Agilent... |